RAZADYNE ER Drug Patent Profile

Which patents cover Razadyne Er, and what generic alternatives are available?

Razadyne Er is a drug marketed by Janssen Pharms and is included in one NDA.

The generic ingredient in RAZADYNE ER is galantamine hydrobromide. There are fifteen drug master file entries for this compound. Nine suppliers are listed for this compound. Additional details are available on the galantamine hydrobromide profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Razadyne Er

A generic version of RAZADYNE ER was approved as galantamine hydrobromide by BARR on August 28^th, 2008.

Summary for RAZADYNE ER

US Patents:	0
Applicants:	1
NDAs:	1

Paragraph IV (Patent) Challenges for RAZADYNE ER

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
RAZADYNE ER	Extended-release Capsules	galantamine hydrobromide	16 mg and 24 mg	021615	1	2006-03-11
RAZADYNE ER	Extended-release Capsules	galantamine hydrobromide	8 mg	021615	1	2006-03-02

US Patents and Regulatory Information for RAZADYNE ER

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Janssen Pharms	RAZADYNE ER	galantamine hydrobromide	CAPSULE, EXTENDED RELEASE;ORAL	021615-001	Apr 1, 2005		DISCN	Yes	No
Janssen Pharms	RAZADYNE ER	galantamine hydrobromide	CAPSULE, EXTENDED RELEASE;ORAL	021615-002	Apr 1, 2005		DISCN	Yes	No
Janssen Pharms	RAZADYNE ER	galantamine hydrobromide	CAPSULE, EXTENDED RELEASE;ORAL	021615-003	Apr 1, 2005		DISCN	Yes	No

International Patents for RAZADYNE ER

See the table below for patents covering RAZADYNE ER around the world.

Country	Patent Number	Title	Estimated Expiration
Eurasian Patent Organization	200100713
Denmark	1140105
Spain	2000428
Germany	3779149
Luxembourg	90710
Poland	349501
Denmark	175839

Supplementary Protection Certificates for RAZADYNE ER

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0236684	C300140	Netherlands		PRODUCT NAME: GALANTAMINE, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZUURADDITIEZOUT, IN HET BIJZONDER GALANTAMINE HYDROBROMIDE; NAT. REGISTRATION NO/DATE: RVG 29073 - RVG 29076 20030702; FIRST REGISTRATION: SE 15561 - 15565 20000225
0236684	2001C/007	Belgium		PRODUCT NAME: GALANTAMINUM HYDROBROMIDUM; NAT. REGISTRATION NO/DATE: 1028 IS 94 F3 20000918; FIRST REGISTRATION: SE 15561 20000301
0236684	3/2001	Austria		PRODUCT NAME: GALANTAMIN ODER SAEUREADDITIONSSALZE DAVON; NAT. REGISTRATION NO/DATE: 1-23748, 1-23749, 1-23750, 1-23751 20000822; FIRST REGISTRATION: SE 15561, 15562, 15563,15565 20000301
0236684	C00236684/01	Switzerland		FORMER REPRESENTANTIVE: E. BLUM AND CO. PATENTANWAELTE, CH
0236684	SPC/GB00/033	United Kingdom		PRODUCT NAME: GALANTHAMINE OR ACID ADDITION SALTS THEREOF; REGISTERED: SE 15561 20000301; SE 15562 20000301; SE 15563 20000301; SE 15565 20000301; UK PL08557/0039 20000914; UK PL08557/0040 20000914; UK PL08557/0041 20000914; UK PL08557/0042 20000914

Razadyne ER (galantamine extended-release): Investment scenario and fundamentals analysis

Last updated: February 3, 2026

Overview
Razadyne ER (galantamine extended-release) is an acetylcholinesterase inhibitor approved by the U.S. FDA for mild to moderate Alzheimer's disease. Marketed primarily by Orphan Pacific and developed by Janssen Pharmaceuticals, Razadyne ER is positioned within the field of symptomatic treatments for neurodegenerative disorders. Its market position is influenced by patent protections, competitive landscape, regulatory status, and emerging pipeline developments.

---

Market Landscape and Revenue Trends

Metric	Data	Source
U.S. Alzheimer’s drug market size (2022)	$7.5 billion	IQVIA
Razadyne ER sales (2022)	Estimated $40–60 million	EvaluatePharma, market reports
Growth rate of Alzheimer’s drugs (CAGR, 2021–2026)	4.2%	GlobalData

Razadyne ER captures a small segment of the Alzheimer’s treatment market. Its sales have plateaued due to generic competition, particularly following patent expiration in 2013. Recent uptake depends on new formulations, regulatory approvals outside the U.S., and pipeline innovations.

---

Regulatory and Patent Status

• Patent lifecycle: Originally protected until 2013. Patent expirations have led to generic erosion.
• Regulatory approvals: The drug remains approved for multiple markets, with ongoing submissions extending its reach.
• Regulatory hurdles: Strict indications limit off-label use; any new formulation or label extension requires substantial data.

---

Competitive Positioning

Competitor	Market Share (2022)	Key Differentiator	Status
Donepezil (Aricept)	55%	Once-daily dosing	Market leader
Rivastigmine (Exelon)	20%	Patch delivery	Generic versions available
Galantamine (Razadyne ER)	8%	Cognitive benefit in mild to moderate AD	Generics dominant since 2013

Razadyne ER's challenge stems from generic competition and limited differentiation. It depends on physician prescribing habits favoring branded formulations for perceived efficacy.

---

Pipeline and Future Potential

• New indications: Trials exploring use in Lewy body dementia and mild cognitive impairment.
• Formulation enhancements: Potential for extended-release or combination therapies.
• Regulatory prospects: Filing for new indications or formulations could restore market share, subject to trial outcomes.

---

Cost and Investment Considerations

• Development costs: High, ongoing R&D for new indications estimated at $150M–$300M per development phase.
• Regulatory risks: FDA approval processes are lengthy and uncertain, with chances of rejection or delays.
• Market access: Reimbursement landscapes favor established drugs; novel formulations need to demonstrate clear patient benefits for coverage approval.
• Patent lifecycle management: Limited window for exclusivity; strategic licensing or collaborations may extend product lifecycle.

---

Financial Fundamentals and Investment Risks

• Revenue sustainability: Past revenues declining due to generic erosion. Future gains hinge on pipeline success or label extensions.
• Profit margins: Likely decreasing, pressured by generic competition and price erosion.
• Market volatility: High, with sensitivity to regulatory decisions and clinical trial outcomes.
• Strategic acquisition potential: Larger pharmaceutical firms may acquire rights for reformulations or new indications.

---

Summary of Investment Outlook

Razadyne ER's valuation depends predominantly on pipeline success and the ability to mitigate generic competition. Current sales are stable but declining. Significant upside exists if new formulations or indications gain regulatory approval, attracting targeted investments. Risks include patent expirations, regulatory hurdles, and limited differentiation against generics.

---

Key Takeaways

• Razadyne ER faces shrinking market share due to patent expiry and generics.
• Growth prospects depend on pipeline developments, including new indications or formulations.
• Strategic collaborations or licensing could expand its market reach.
• Financial returns are sensitive to regulatory outcomes and market acceptance of innovations.
• The short horizon warrants cautious positioning; long-term upside hinges on pipeline momentum.

---

FAQs

1. What are the main drivers of Razadyne ER’s sales decline?
Patent expiration in 2013 led to generic competition, which significantly eroded sales. Limited differentiation from generics and no new indications have contributed to stagnation.

2. How does Razadyne ER compare to its competitors?
It has a smaller market share (around 8%) compared to donepezil (55%) and rivastigmine (20%), largely due to patent loss and the commoditization of acetylcholinesterase inhibitors.

3. What are potential catalysts for future growth?
Regulatory approval of new indications, formulation innovations such as combination therapies, and strategic licensing agreements could stimulate revenue.

4. What are the primary risks associated with investing in Razadyne ER?
Patent expiry, failure to secure new indications, market erosion due to generics, and regulatory delays pose significant risks.

5. Is there a realistic pathway for Razadyne ER to regain market prominence?
Regulatory approval for novel indications or improved formulations, coupled with effective marketing strategies and partnerships, could enhance its market position.

---

Sources

1. IQVIA. “The IQVIA Institute Report: The State of the Pharma Market 2022.”
2. EvaluatePharma. “Top-Selling Drugs: 2022 Edition.”
3. GlobalData. “Alzheimer’s Disease Market Forecast 2021–2026.”
4. FDA. “Razadyne (galantamine) Extended-Release Tablets — Drug Approvals & Labeling.”